These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 7604791)

  • 1. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
    Raiteri M; Arnaboldi L; Quarato P; Paoletti R; Fumagalli R; Corsini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():35S-42S. PubMed ID: 8562263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
    Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
    Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.
    Rogler G; Lackner KJ; Schmitz G
    Am J Cardiol; 1995 Jul; 76(2):114A-116A. PubMed ID: 7604784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct vascular effects of HMG-CoA reductase inhibitors.
    Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
    Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages.
    Bernini F; Scurati N; Bonfadini G; Fumagalli R
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1352-8. PubMed ID: 7670949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
    Yasunari K; Maeda K; Minami M; Yoshikawa J
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
    Hughes AD
    J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.
    Soma MR; Parolini C; Donetti E; Fumagalli R; Paoletti R
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S20-4. PubMed ID: 8907210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
    Soma MR; Donetti E; Parolini C; Mazzini G; Ferrari C; Fumagalli R; Paoletti R
    Arterioscler Thromb; 1993 Apr; 13(4):571-8. PubMed ID: 8466892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
    Hidaka Y; Eda T; Yonemoto M; Kamei T
    Atherosclerosis; 1992 Jul; 95(1):87-94. PubMed ID: 1642695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
    Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
    Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
    Colli S; Eligini S; Lalli M; Camera M; Paoletti R; Tremoli E
    Arterioscler Thromb Vasc Biol; 1997 Feb; 17(2):265-72. PubMed ID: 9081680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.